The partnership will focus on advancing cancer research using AI.

CARY, NORTH CAROLINA, UNITED STATES, January 16, 2024 /EINPresswire.com/ -- In a pivotal stride toward advancing cancer care, Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sphere^®, a nonprofit initiative of the CEO Roundtable on Cancer, have announced their partnership to augment tumor assessments using AI-enabled solutions for clinical trials and cancer care. The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments, ultimately improving the quality of care for patients.

The focus of this collaboration is autoRECIST, a product of Project Data Sphere’s Images and Algorithms program. The program, initiated in consultation with the U.S. Food and Drug Administration, includes stakeholders and experts from across the pharmaceutical industry and academia. In collaboration with Qure.ai, autoRECIST will address the critical need for automating and standardizing tumor response assessments in medical imaging to enhance cancer treatment and research. Rooted in current imaging guidelines, this AI clinical tool will aid radiologists in the detection, selection, measuring and tracking of lesions using defined criteria.

autoRECIST can improve clinical trials and cancer treatments through:

• Enhanced efficiency and improved accuracy through the automation of analyzing medical images (such as CT scans) and reducing variability when measuring tumor size and changes over time.

• Faster decision-making in the assessment of tumor response, which enables researchers and clinicians to quickly determine if a treatment is effective or if changes in care are required.

This collaboration enables the sharing of unique insights, advanced methodologies and access to a broader network of industry leaders, further enriching the development of the autoRECIST solution.

“We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients,” said Jon McDunn, PhD, president of Project Data Sphere. “The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.”

“Collaborating with Project Data Sphere marks a pivotal moment in the evolution of cancer treatment, harnessing the transformative power of artificial intelligence,” said Prashant Warier, CEO and cofounder of Qure.ai. “Our development of autoRECIST is testament to our unwavering commitment to combating cancer. This groundbreaking AI innovation is set to revolutionize the evaluation of treatment efficacy in cancer patients. With a resolute focus on early detection, we're leveraging our data science expertise to significantly advance clinical trial methodologies, ultimately changing the landscape of cancer care.”

This collaboration signifies a concerted effort by Qure.ai and Project Data Sphere to make substantial advancements in cancer care and elevate patient outcomes. The integration of AI technology into the evaluation process holds the potential to reshape the landscape of cancer clinical trials and generate more effective treatments for those affected by cancer.

About Project Data Sphere
Project Data Sphere (PDS) is an independent initiative of the CEO Roundtable on Cancer, a nonprofit organization founded to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to the best available treatments, and hasten the discovery of novel and more effective anti-cancer therapies. In addition to operating an open-access data-sharing platform, PDS manages research programs that explore leading issues in oncology using machine learning tools and big data analytics. For more information, visit www.projectdatasphere.org.

About Qure.ai
Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) tools to make healthcare more accessible and affordable to patients around the world in medical imaging & care coordination. Our technology fulfils a pertinent, unmet need in the radiology industry. With the aid of tools like those developed by Qure.ai, which work via a sophisticated set of algorithms that can instantly evaluate scans to prioritize actionable patient cases quickly, radiologists can focus their time and advanced skill sets on the most pressing diagnoses.

Mark Slagle
CEO Roundtable on Cancer
+1 919-360-7343
email us here
Visit us on social media:
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.